WallStreetZenWallStreetZen

NASDAQ: PASG
Passage Bio Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for PASG

Based on 3 analysts offering 12 month price targets for Passage Bio Inc

Min Forecast
$4.00+740.34%
Avg Forecast
$7.67+1,510.71%
Max Forecast
$13.00+2,631.09%

Should I buy or sell PASG stock?

Based on 3 analysts offering ratings for Passage Bio Inc.

Strong Buy
Strong Buy
2 analysts 66.67%
Buy
1 analysts 33.33%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their PASG stock forecasts and price targets.

PASG stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2025-03-04
lockedlocked$00.00+00.00%2024-11-29
lockedlocked$00.00+00.00%2024-11-14

1 of 1

Forecast return on equity

Is PASG forecast to generate an efficient return?

Company
-41.59%
Industry
145.94%
Market
89.52%
PASG's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is PASG forecast to generate an efficient return on assets?

Company
-24.88%
Industry
32.64%
PASG is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

PASG earnings per share forecast

What is PASG's earnings per share in the next 3 years based on estimates from 2 analysts?

Avg 1 year Forecast
-$0.78
Avg 2 year Forecast
-$0.55
Avg 3 year Forecast
-$0.44

PASG revenue forecast

What is PASG's revenue in the next 3 years based on estimates from 1 analyst?

Avg 1 year Forecast
$5.0M
Avg 2 year Forecast
$38.4M
Avg 3 year Forecast
$111.0M

PASG vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
PASG$0.48$7.67+1,510.71%Strong Buy
INTS$1.93$6.75+249.74%Strong Buy
RLYB$0.70$5.00+614.29%Buy
PYPD$2.85$10.50+268.42%Buy
UBX$1.70$7.00+311.76%Strong Buy
View Top Biotech Stocks

Passage Bio Stock Forecast FAQ

Is Passage Bio Stock a good buy in 2025, according to Wall Street analysts?

The consensus among 3 Wall Street analysts covering (NASDAQ: PASG) stock is to Strong Buy PASG stock.

Out of 3 analysts, 2 (66.67%) are recommending PASG as a Strong Buy, 1 (33.33%) are recommending PASG as a Buy, 0 (0%) are recommending PASG as a Hold, 0 (0%) are recommending PASG as a Sell, and 0 (0%) are recommending PASG as a Strong Sell.

If you're new to stock investing, here's how to buy Passage Bio stock.

What is PASG's earnings growth forecast for 2025-2027?

(NASDAQ: PASG) Passage Bio's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 14.15%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 18.9%.

Passage Bio's earnings in 2025 is -$64,767,000.On average, 2 Wall Street analysts forecast PASG's earnings for 2025 to be -$48,164,912, with the lowest PASG earnings forecast at -$48,475,654, and the highest PASG earnings forecast at -$47,854,171. On average, 2 Wall Street analysts forecast PASG's earnings for 2026 to be -$33,870,809, with the lowest PASG earnings forecast at -$34,181,551, and the highest PASG earnings forecast at -$33,560,068.

In 2027, PASG is forecast to generate -$27,345,241 in earnings, with the lowest earnings forecast at -$27,345,241 and the highest earnings forecast at -$27,345,241.

What is PASG's revenue growth forecast for 2029-2031?

(NASDAQ: PASG) Passage Bio's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 60.04%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.85%.

Passage Bio's revenue in 2025 is $0.On average, 1 Wall Street analysts forecast PASG's revenue for 2029 to be $308,255,439, with the lowest PASG revenue forecast at $308,255,439, and the highest PASG revenue forecast at $308,255,439. On average, 1 Wall Street analysts forecast PASG's revenue for 2030 to be $2,385,872,239, with the lowest PASG revenue forecast at $2,385,872,239, and the highest PASG revenue forecast at $2,385,872,239.

In 2031, PASG is forecast to generate $6,899,701,379 in revenue, with the lowest revenue forecast at $6,899,701,379 and the highest revenue forecast at $6,899,701,379.

What is PASG's forecast return on assets (ROA) for 2025-2028?

(NASDAQ: PASG) forecast ROA is -24.88%, which is lower than the forecast US Biotechnology industry average of 32.64%.

What is PASG's Price Target?

According to 3 Wall Street analysts that have issued a 1 year PASG price target, the average PASG price target is $7.67, with the highest PASG stock price forecast at $13.00 and the lowest PASG stock price forecast at $4.00.

On average, Wall Street analysts predict that Passage Bio's share price could reach $7.67 by Mar 4, 2026. The average Passage Bio stock price prediction forecasts a potential upside of 1,510.71% from the current PASG share price of $0.48.

What is PASG's Earnings Per Share (EPS) forecast for 2025-2027?

(NASDAQ: PASG) Passage Bio's current Earnings Per Share (EPS) is -$1.07. On average, analysts forecast that PASG's EPS will be -$0.78 for 2025, with the lowest EPS forecast at -$0.78, and the highest EPS forecast at -$0.77. On average, analysts forecast that PASG's EPS will be -$0.55 for 2026, with the lowest EPS forecast at -$0.55, and the highest EPS forecast at -$0.54. In 2027, PASG's EPS is forecast to hit -$0.44 (min: -$0.44, max: -$0.44).

What is PASG's forecast return on equity (ROE) for 2025-2028?

(NASDAQ: PASG) forecast ROE is -41.59%, which is considered weak.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.